QPPV.COM KNOWLEDGE ASSESSMENT

EU Risk Management Plan Structure and Governance Knowledge Assessment

Test your understanding of the concepts covered by EU Risk Management Plan Structure Explained.

Question 1 of 10Pass mark: 80%

Question 1 of 10 What is the primary purpose of a traceability matrix in an RMP?

To replace the statistical analysis plan for each PASS To map each pharmacovigilance activity and risk minimisation measure to the safety concern and rationale that support it To list all employees involved in pharmacovigilance without recording responsibilities To demonstrate that every adverse event has resulted in a label change

Question 2 of 10 Which statement best describes the role of Part IV?

It contains the complete Safety Specification for all products It addresses post-authorisation efficacy studies when efficacy uncertainty may influence the benefit-risk assessment It is the mandatory location for all PASS protocols It provides the public-facing summary of risk minimisation materials

Question 3 of 10 Which relationship between Parts II, III and V best reflects the operational logic of an EU-RMP?

Part II identifies what matters; Part III explains how further safety information will be obtained; Part V explains how risks will be minimised Part II contains risk minimisation materials; Part III contains the public summary; Part V contains only clinical trial results Part II is administrative; Part III is limited to efficacy; Part V replaces the product information Each part is developed independently so that changes in one part do not require review of the others

Question 4 of 10 Which categorisation is most consistent with an Important Identified Risk?

A clinically meaningful risk for which a causal association with the product is established A theoretical concern supported only by a pharmacological hypothesis A population for which no safety data exist but no concern has been identified An efficacy endpoint that may affect treatment adherence

Question 5 of 10 Which evidence would best demonstrate that a PASS is being conducted in an inspection-ready manner?

Only the approved RMP title page A protocol, study agreements, monitoring records, status reports and documented interim or final analyses A general statement that the study is progressing as planned A list of unrelated adverse events from the product database

Question 6 of 10 Which item would generally be considered a routine pharmacovigilance activity rather than an additional activity?

A prospective cohort PASS with scheduled laboratory testing A disease-specific registry established to quantify a safety outcome Routine individual case safety report processing and signal management A sentinel surveillance network created for active case finding

Question 7 of 10 A local affiliate continues using an outdated patient leaflet after a revised RMP measure has been approved. Which governance control would most directly prevent or detect this problem?

Removing all version numbers from the materials Maintaining change control, distribution lists and implementation confirmations for current materials Relying solely on the next periodic safety report Allowing each affiliate to modify the material independently

Question 8 of 10 Which statement best explains the feedback loop between signal management, the RMP and benefit-risk evaluation?

Signals may prompt RMP changes, while results from RMP activities inform subsequent benefit-risk assessments and regulatory communications Signal management is separate from RMP governance and should not influence RMP content RMP activities are performed only after all benefit-risk decisions are final Benefit-risk evaluation uses only pre-authorisation clinical trial data

Question 9 of 10 In the DILI example, why are baseline and scheduled liver function tests important to both the PASS and risk minimisation strategy?

They provide data for characterisation and support early detection that may permit intervention before severe injury They eliminate the need for spontaneous reporting They prove that every ALT elevation is caused by the product They are required only to measure prescriber awareness

Question 10 of 10 Which approach best supports a credible evaluation of whether DILI risk minimisation reduced severe outcomes?

Compare pre- and post-implementation incidence using defined data sources and an analysis adjusted for relevant factors where appropriate Count the number of leaflets printed without assessing patient exposure Use only anecdotal reports from a single prescriber Assess effectiveness solely by whether the RMP was submitted on time

EU Risk Management Plan Structure and Governance Knowledge Assessment

Cookie Settings